{"filings":[{"id":509156,"accession_number":"0001493152-26-024363","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-05-19T12:38:18+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Oragenics dosed first patient in Phase IIa concussion trial; signs LOI for CNS device","event_type":"other_material","confidence":"high","bullets":["Phase IIa trial of ONP-002 in Australia active; first patient dosed at Mackay Base Hospital March 2026.","Signed LOI to license a complementary CNS medical device; expands addressable indication set beyond ONP-002.","Cash balance $6.1M as of Q1 2026; R&D expenses $0.6M (up 89% YoY); G&A $1.6M (down 4% YoY).","Targets Type C meeting with FDA in Q2 2026, IND submission by end of 2026, Phase IIa data readout in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91680,"accession_number":"0001493152-26-021627","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics signs LOI to license CardioDialysis from Sigyn Therapeutics for TBI","event_type":"m_and_a","confidence":"high","bullets":["LOI grants Oragenics exclusive license for CardioDialysis blood purification tech in TBI and chronic neurodegenerative diseases.","Consideration: 3,250,000 shares of preferred stock convertible 1:1 to common, plus 3% royalty for 6 years post-FDA clearance.","Target closing within 90 days; Sigyn exclusivity during that period; subject to due diligence, board approvals, and NYSE American rules.","Oragenics also advancing ONP-002 (Phase IIa intranasal neurosteroid); combined approach targets TBI inflammation on both sides of BBB.","No FDA-approved pharmacological treatment for concussion/mTBI; 69 million brain injuries occur annually worldwide."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91679,"accession_number":"0001493152-26-016294","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics dosed first patient in Phase IIa trial of ONP-002 for mild traumatic brain injury","event_type":"other_material","confidence":"high","bullets":["First patient dosed at Mackay Hospital (Australia) days after site activation on March 31, 2026.","Phase IIa is randomized, placebo-controlled, targeting 40 patients; dosing within 12 hours of concussion.","Additional sites (Alfred Hospital, Royal Adelaide Hospital) expected to activate in Q2 2026.","Company plans to submit IND to FDA in Q4 2026 for U.S. Phase IIb trials.","Phase 1 safety data showed zero serious adverse events across all dose levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101917,"accession_number":"0001493152-26-014128","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["5.08","9.01"],"status":"ready","headline":"Oragenics sets 2025 annual meeting for June 29, 2026; new deadline for shareholder proposals May 1, 2026","event_type":"other","confidence":"high","bullets":["Board scheduled 2025 Annual Meeting for June 29, 2026, more than 30 days from 2024 meeting anniversary.","Shareholder proposals under Rule 14a-8 must be received by May 1, 2026.","Proposals should be delivered to Oragenics' principal executive office in Lakewood Ranch, FL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101916,"accession_number":"0001493152-26-009682","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics gets HREC approval, starts Phase IIa site activation for ONP-002 in Australia; explores CNS asset acquisition","event_type":"other_material","confidence":"high","bullets":["Received final HREC approval in Australia for Phase IIa trial of ONP-002 for concussion/mTBI.","Completed first site initiation visit (SIV) for Phase IIa trial; two more sites in final RGO review.","Phase IIa trial of 40 patients; first dose within 12 hours of injury; data readout expected before year-end 2026.","Exploring discussions with third parties for potential acquisition of CNS assets focusing on brain health/recovery.","No definitive agreements reached; platform expansion independent of Receptor.AI partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101915,"accession_number":"0001493152-26-003237","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oragenics extends ATM equity distribution agreement with Dawson James","event_type":"other_material","confidence":"high","bullets":["On January 22, 2026, Oragenics amended its at-the-market sales agreement with Dawson James Securities.","The amendment extends the agreement term until all shares are sold or the shelf registration expires.","No other terms of the original October 11, 2024 agreement were modified.","The ATM facility allows the company to sell common stock from time to time on NYSE American."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101914,"accession_number":"0001493152-26-002759","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oragenics CEO presents at Sequire Investor Summit; filing lacks specific financial data","event_type":"other_material","confidence":"low","bullets":["CEO presented at Sequire Investor Summit on January 20, 2026, using a new corporate presentation.","Presentation filed as Exhibit 99.1 and will be hosted on the company website under 'Presentations'.","No specific financial results, guidance, or operational milestones were detailed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118252,"accession_number":"0001493152-25-027745","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Oragenics board boosts CEO salary 5% to $341,250, awards bonus and options","event_type":"other","confidence":"high","bullets":["CEO Janet Huffman base salary increased 5% from $325,000 to $341,250 effective Jan 1, 2026.","CEO awarded $110,500 bonus for FY2025 performance against goals.","CEO granted options for 250,000 shares at $0.93, vesting over 3 years.","Each non-employee director received immediately vested options for 125,000 shares at $0.93.","Director Giordano received onboarding option award worth $30,000 at prior closing price (vested immediately)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118251,"accession_number":"0001493152-25-021749","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics regains NYSE compliance, raises $16.5M, partners with Receptor.AI, advances Phase IIa trial","event_type":"other_material","confidence":"high","bullets":["Regained NYSE American compliance on Oct 20, 2025, resolving equity deficiency and removing below-compliance indicator.","Completed $16.5M gross capital raise via Series H Convertible Preferred Stock in July 2025; net proceeds ~$15.2M.","Eliminated $3M note payable and restored stockholder equity above the $6M NYSE threshold.","Formed strategic collaboration with Receptor.AI to use AI-driven discovery for pipeline beyond concussion.","Anticipates Phase IIa trial initiation for ONP-002 in Q4 2025/Q1 2026 in Australia, with U.S. Phase IIb planning underway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118250,"accession_number":"0001493152-25-018725","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["1.01","3.01","7.01","9.01"],"status":"ready","headline":"Oragenics settles Ladenburg dispute for $700K; regains NYSE American compliance","event_type":"other_material","confidence":"high","bullets":["Paid $700K to Ladenburg Thalmann to settle $2.5M fee dispute; mutual release and arbitration dismissal.","Regained compliance with NYSE American Section 1003(a) as stockholders' equity exceeds $6M as of Oct 18, 2025.","Compliance restored after $16.5M Series H Preferred Stock offering in July 2025; .BC indicator to be removed.","Company now focusing on advancing ONP-002 concussion treatment into Phase IIa trials in Australia and planning U.S. Phase IIb."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134693,"accession_number":"0001493152-25-012562","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Oragenics appoints Natasha Giordano to board of directors effective Sept 1, 2025","event_type":"leadership","confidence":"high","bullets":["Natasha Giordano appointed to Oragenics Board effective September 1, 2025.","Ms. Giordano brings experience from PLx Pharma (CEO), Matinas BioPharma board, and HCA.","She will receive annual base director fee of $45,000, pro-rated, and $3,750/month for Sept-Dec 2025.","She has agreed to stand for re-election at next annual meeting of shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134692,"accession_number":"0001641172-25-022908","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics raises $16.5M, advances ONP-002 Phase IIa concussion trial for Q3 2025","event_type":"other_material","confidence":"high","bullets":["Raised $16.5M via Series H Preferred Stock and Warrants; net proceeds ~$15.2M after fees.","HREC approval secured in Australia; Southern Star Research appointed CRO; Sterling Pharma Solutions for cGMP manufacturing.","Phase IIa trial initiation anticipated Q3 2025; IND submission for Phase IIb expected Q3-Q4 2025.","Six months ended June 30, 2025: R&D expenses down 50%, G&A costs down 8%, net losses down 6% YoY.","No FDA-approved pharmacological treatment currently exists for concussion; market opportunity $8.9B by 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134691,"accession_number":"0001641172-25-017575","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["1.01","3.03","5.03","8.01","9.01"],"status":"ready","headline":"Oragenics closes $16.5M public offering of Series H Preferred Stock and Warrants","event_type":"other_material","confidence":"high","bullets":["Issued 660,000 shares of Series H Convertible Preferred Stock at $25/unit with warrants to buy 660,000 additional shares.","Preferred Stock converts to common at $2.50 per share; warrants exercise at $25/share for 5 years.","Gross proceeds ~$16.5M; net ~$15M after fees; potential additional $16.5M if all warrants exercised.","Net proceeds to fund ONP-002 concussion trials, repay $3M bridge note, and general corporate purposes.","Preferred Stock carries 9% cumulative dividend payable in common stock; no voting rights except as law requires."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151601,"accession_number":"0001641172-25-012596","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Oragenics approves 1-for-30 reverse stock split to meet NYSE American listing standards","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-30 ratio; effective 12:01 a.m. ET on June 3, 2025.","Outstanding shares reduced from ~21.5M to ~715,843 post-split; fractional shares rounded up.","Split intended to boost share price and meet NYSE American continued listing standards.","Trading symbol remains OGEN; new CUSIP 684023 609."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151600,"accession_number":"0001641172-25-011774","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Oragenics furnishes Neurotrauma Medicine presentation; no specifics disclosed","event_type":"other_material","confidence":"low","bullets":["Presentation on Neurotrauma Medicine provided for Scientific Advisory Board webinar on May 20, 2025.","No financial or operational data included in the filing or exhibit.","Presentation posted under 'Presentations' section of oragenics.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151599,"accession_number":"0001641172-25-008389","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["1.01","5.02","5.07","9.01"],"status":"ready","headline":"Oragenics appoints Janet Huffman as permanent CEO; shareholders authorize reverse stock split up to 1:50","event_type":"leadership","confidence":"high","bullets":["Janet Huffman, previously CFO and Interim CEO, appointed permanent CEO effective May 2, 2025 under one-year agreement.","Base salary $325,000, bonus target up to 50% of base, severance includes 6 months salary and change-in-control provisions.","Shareholders authorized a reverse stock split of common stock between 1:5 and 1:50 ratio, Board to determine exact ratio.","Authorized increase in authorized shares to 350M contingent on reverse split; 2021 Equity Incentive Plan shares increased to 3,166,667.","All five directors re-elected: Pope, Telling, Koski, Dunton, Gandolfo. Auditor Cherry Bekaert ratified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151598,"accession_number":"0001641172-25-003334","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics submits Phase II concussion trial protocol to NZ ethics committee","event_type":"other_material","confidence":"high","bullets":["Submitted clinical trial protocol to Health and Disability Ethics Committee (HDEC) in New Zealand for Phase II trial of ONP-002 for mild traumatic brain injury.","Pending HDEC approval, expects to initiate patient enrollment at Christchurch Hospital, one of the busiest emergency departments in Australasia.","ONP-002 is an intranasal neurosteroid therapy; no approved pharmaceutical exists for concussion, an unmet medical need.","Phase I study showed safety and tolerability; Phase II will evaluate efficacy in mTBI patients.","Company plans to expand global clinical footprint with sites in both Australia and New Zealand."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170450,"accession_number":"0001641172-25-000855","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics Q1 update: $5M raised, ONP-002 Phase IIa trial advances","event_type":"other_material","confidence":"high","bullets":["Raised ~$2.6M via ATM equity and ~$2.25M via non-dilutive debt; submitted DoD grant for concussion program.","Submitted Investigator's Brochure for Phase IIa trial in Australia; trial listed on ClinicalTrials.gov; awaiting HREC approval.","Partnered with BRAINBox Solutions to combine intranasal ONP-002 with diagnostic biomarkers for personalized concussion care.","Upcoming milestones: HREC approval and first patient enrollment in Q2 2025; Phase IIa enrollment completion by Q4 2025.","Simplified capital structure by converting all preferred shares to common; annual meeting set for May 2, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170449,"accession_number":"0001493152-25-009335","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Oragenics submits Investigator's Brochure for Phase II trial of ONP-002 in Australia","event_type":"other_material","confidence":"high","bullets":["Phase II trial of intranasal neurosteroid ONP-002 for mild traumatic brain injury (mTBI); up to 40 participants enrolled across two arms.","Trial is randomized, double-blind, placebo-controlled; nine doses over five days, first dose within 12 hours of injury.","Prior Phase I confirmed safety and tolerability at multiple intranasal doses in healthy adults.","No FDA-approved drug therapies currently exist for concussion, an unmet medical need.","Interim CEO Janet Huffman anticipates final regulatory approvals in coming weeks to initiate trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170448,"accession_number":"0001493152-25-007182","cik":1174940,"company_name":"ORAGENICS INC","ticker":"OGEN","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["5.08","9.01"],"status":"ready","headline":"Oragenics sets 2024 Annual Meeting for May 16, 2025; shareholder proposal deadline March 14","event_type":"other","confidence":"high","bullets":["Board scheduled 2024 Annual Meeting for May 16, 2025, over 30 days later than 2023 meeting anniversary.","Shareholder proposals under Rule 14a-8 must be received by March 14, 2025.","Proposals to be sent to Oragenics principal office: 1990 Main Street, Suite 750, Sarasota, FL 34236.","Record date and location will be stated in the proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}